Merck
Fusion Pharmaceuticals, Merck to Study Targeted Radiation, Keytruda Combo in Certain Solid Cancers
The companies will conduct a Phase I/II clinical trial to evaluate Fusion's FPI-1434 and Merck's checkpoint inhibitor in solid tumors expressing IGF-1R.
FDA Approves Keytruda-Herceptin Combination for HER2-Positive Gastric, Gastroesophageal Cancer
The agency granted accelerated approval to Merck's pembrolizumab plus Herceptin and chemotherapy for patients with advanced, HER2-positive gastric cancer.
FDA Expert Panel Votes Against Keytruda Accelerated Approval for PD-L1-Positive Gastric Cancer
The ODAC voted to remove the accelerated approval due to the absence of demonstrated overall survival benefit in confirmatory clinical trials.
TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis
In a retrospective analysis, tumor mutational burden was not associated with improved responses to combination immunotherapy, researchers found.
In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.Â